BioCorRx Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioCorRx Inc. | ||
| Date: April 1, 2024 | By: | /s/ Lourdes Felix |
|---|---|---|
| Lourdes Felix | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Position | Date |
|---|---|---|
| /s/ Lourdes Felix | Chief Executive Officer, Chief Financial Officer, and Director | April 1, 2024 |
| Lourdes Felix | (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer) | |
| /s/Brady Granier | Director and President (resigned on January 31, 2024) | April 1, 2024 |
| Brady Granier | ||
| /s/ Kent Emry | Director | April 1, 2024 |
| Kent Emry | ||
| /s/ Luisa Ingargiola | Director | April 1, 2024 |
| Luis Ingargiola | ||
| /s/ Louis Lucido | Director, Interim President from January 5, 2024 to January 31, 2024, and President effective on February 1, 2024 | April 1, 2024 |
| Louis Lucido | ||
| /s/ Joseph J. Galligan | Director | April 1, 2024 |
| Joseph J. Galligan | ||
| /s/ Harsha Murthy | Director | April 1, 2024 |
| Harsha Murthy | ||
BIOCORRX, INC.
TABLE OF CONTENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID 688) | F-1 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Deficit for the Years Ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.